E-mail: sales@rongxinbio.com
Product Categories

Rongxin Bio-Tech Co.,Ltd(H.K.)

FAX: 029-62388781

FEL: +8618220537895

E-mail: sales@rongxinbio.com

Address: Xi'an Jianshe Mansion,China, Shaanxi Sheng, Xian Shi, Yanta Qu, QuJiang ShangQuan, Yanta S Rd

Home > Knowledge > Content
How do semeglutide treat diabetes to lose weight?
- Nov 14, 2022-

Semeglutide is a new type of GLP-1 analog of underpinning once a week. Semeglutide is a long-acting GLP-1 analog of long-acting GLP-1 developed by Nuo and Nord. Compared with Lichel peptides, Semeglutide is a longer fat chain and increased hydrophobicity. After PEG modification, it can not only be closely combined with albumin, cover up the dpP-4 enzyme hydrolysis point, but also reduce the renal excretion, which can extend the effect of the biological half-life and achieve a long cycle. Noromo's Samalu peptide hangs DPP-4's Sigerine, and the GLP-1 originator long-acting Essean peptide (should be designed with Lilly's Trulicity head-to-head comparison, bullying has long been listed). In the test, high -dose Soma dropped A1C1.6%, reducing up to 6kg in weight. The Semeglutide test inspected 1.0mgsemeglutide from 813 patients with type 2 diabetes. Compared with 2.0mg Essean peptides per week, the test cycle was 56 weeks. Diabetic drugs. In December 2017, the FDA officially approved the one-week GLP-1 drop-hypoglycemic medicine Semeglutide, which was developed by Novonordisk, was listed on the market. The product was named OZEMPIC. According to clinical trial data, compared with the placebo, Januvia in the United States, ByDureon in Astraon and Lantus of Sanofi, Ozempic can reduce the HBA1C level. The drug CHEMICALBOOK also shows the ability to help patients lose weight. As a leader in the field of diabetes, Novonordisk not only in the field of insulin, but also the person developed by Liraglutide (commodity name) : Victoza), since its listing in 2009, it has always occupied the GLP-1 market. In 2016, global sales reached US $ 3.2 billion, which can be described as fruitful. The Lichel -peptide compounds have expired, and the generic drug companies are staring at. In order to prevent it before, Novo Nord has already prepared the next generation of Leratan peptide, which is Somalugin. From a structural point of view, Semeglutide is an 8-bit AIB on the GLP-1 (7-37) chain replacing ALA. The 34-bit ARG replaces LYS, and the 26-bit LYS connects the ectumane fat chain. Compared with Liraglutide, Semeglutide has longer fat chains and increase hydrophobicability, but Semeglutide is greatly enhanced by short -chain PEG modification. After PEG modification, it can not only be closely combined with albumin, cover up the dpP-4 enzyme hydrolysis point, but also reduce the renal excretion, which can extend the effect of the biological half-life and achieve a long cycle. According to analysis, OZEMPIC is expected to become one of the best -selling drugs in 2017. Novo Nord predicted that drug sales in 2022 reached 2.2 billion US dollars. At the same time, Novo Nord is actively developing the oral dosage form of Semeglutide, and gradually consolidates its dominance in the diabetic field.

IMG_4915

Leralugin achieved a 5%weight loss effect in patients with BMI ≥ 30, and Semeglutide achieved a weight loss effect of more than 15%in phase II research; 1 subcutaneous injection of Somarugin 0.05 ~ 0.4mg/d, 52 weeks of treatment and follow -up for 7 weeks, which can reduce the average obesity patients with a average base line of 111kg by 16.2%(17.8kg), while exercise and diet combined comfort comfort The dosage group only reduces 2.3%


Where to buy from?

Our company Hongkong RongXin Bio-Tech Co.,Ltd started with a mission: to bring the chemically purest anabolic steroid raw powder, human growth hormone, human growth peptide and API to the world. If you need our products please contact us:

connect:

Enterprise mailbox:sell@rongxinbio.com

Skype:sell@rongxinbio.com

Whatsapp:+86-18191385298